GMALL  Register/Biomaterialdatenbank, Prospektive Datenerfassung, 
Diagnostik, Behandlung und Krankheitsverlauf der ALL des Erw.

AMG103
20180257

A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults with Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

2019‐004780‐52

EVOLVE

A multicentre, randomized trial in adults with de novo Philadelphia- Chromosome positive acute lymphoblastic leukemia to assess the efficacy of ponatinib versus imatinib in combination with low-intensity chemotherapy, to compare subsequent allogeneic stem cell transplantation (SCT) versus TKI in combination with blinatumomab and chemotherapy in optimal responders and to evaluate Blinatumomab before SCT in suboptimal responders (GMALL-EVOLVE)

NCT06061094

Mosaic
TUD-MOSAIC-075

Midostaurin + Gemtuzumab Ozogamicin als Erstlinientherapie für Patienten mit
Akuter Myeloischer Leukämie (AML)

Eudract Nr. 2019-003863-23

Prospektive randomisierte Multicenter Phase III-Studie mit Decitabine und Venetoclax in Kombination with All-transRetinsäure (ATRA) oder Placebo bei Patienten mit akuter myeloischer Leukämie, bei denen keine Induktions-Chemotherapie möglich ist

Eudract Nr. 2020-005495-36

A Phase 1 Single-Arm, Open-Label Study of CA-4948 in Combination with Azacitidine and Venetoclax in Acute Myeloid Leukemia Patients in Complete Response with Measurable Residual Disease

Eudract Nr. 2023-505828-58

CLL18
MOIRAI

Phase III

A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab
vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously
untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual
residual disease for adjustment of treatment duration to improve outcomes

2023-510294-34-00  

BGB-11417-303

III

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/​or Refractory Chronic Lymphocytic Leukemia/​Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

EU-CT-Nummer:  2024-517131-52

Register zur Blastenkrise bei Patienten mit Chronischer Myeloischer Leukämie (CML)

NCT03869502

ELVN-001

A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia (CML)

NCT05304377

Eine klinische Prüfung der Phase I zur Beurteilung der Sicherheit, Verträglichkeit,
Pharmakokinetik und Wirksamkeit von TERN-701 bei Teilnehmern
mit chronischer myeloischer Leukämie

Eudract Nr. 2023-507677-18-00

ASCANY

REGISTER 

Deutsches prospektives Register für Patienten mit chronischer myeloischer Leukämie (CML),
die zuvor mit ≥ 2 TKIs behandelt wurden und auf einen anderen TKI umgestellt wurden

Kumquat 
KQB198-102

Phase I/II

KQB198 als Monotherapie und in Kombination bei fortgeschrittenen hämatologischen malignen Erkrankungen

NCT06645886

Phase-II-Studie zur individualisierten Immuntherapie beim ungünstigen klassischen Hodgkin-Lymphom (INDIE) im Frühstadium

NCT04837859

CA056-025

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD)

NCT05949684

EMN30
MajesTEC-4

Teclistamab + Lenalidomide and Teclistamab Mono versus Lenalidomide Mono in NDMM as Maintenance Therapy Following Autologous Stem Cell Transplantation

Eudract Nr. 2021-002531-27

DSMM XVIII
GMMG-HD9

Randomisierte Phase 3-Studie zur Untersuchung einer Erhaltungstherapie mit Iberdomid versus Iberdomid plus Isatuximab nach autologer hämatopoetischer Blutstammzelltrans-plantation für Patienten mit neudiagnostiziertem Multiplem Myelom

Eudract Nr. 2023-507402-13-00

IM048-022

A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy After Autologous Stem Cell Transplantation (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance)

2022-501515-14-00

MAGNETISMM-32
C1071032

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

EU CT 2023-507871-23-00

DREAMM 10

Phase III

Eine randomisierte, offene Phase-III-Studie zu Belantamab Mafodotin bei Verabreichung in Kombination mit Lenalidomid und Dexamethason (BRd) im Vergleich zu Daratumumab, Lenalidomid und Dexamethason (DRd) bei Teilnehmern mit neu diagnostiziertem multiplem Myelom, die für eine autologe Stammzelltransplantation nicht in Frage kommen (TI-NDMM)

2024-516030-35-00  

TL-895-201

A Phase 2 Multicenter Study of TL-895 in Subjects with Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis, Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis, or Indolent Systemic Mastocytosis

NCT04655118

XPORT-MF-044

A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate thrombocytopenia

NCT05980806

POESIS
KRT-232-115

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post-ET-MF) Following a Suboptimal Response to Ruxolitinib

Eudract Nr. 2023-504724-25

GSK220752
Odyssey

Phase II

Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis

2024-518225-15

OptiMATe
SCC215

Phase III

Optimierung der Induktionstherapie mit MATRix (Methotrexat, Ara-C, Thiotepa, Rituximab) durch De-Eskalation bei primären 
ZNS-Lymphomen - eine randomisierte Phase III Studie

PRIME-CAR

Phase II

Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (PRIME-CAR)

NCT06912529

CA073-1003
Golseek-4

Phase III

A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) Vs Investigator’s Choice in Participants with Relapsed/Refractory Follicular Lymphoma

 Eudract Nr. 2024-519152-82

MorningLyte

Phase III

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 (MorningLyte)

 Eudract Nr. 2023-505436-35

CLEAR

II

Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

EU-CT-Nummer:  2023-509861-19-01

BGB-16673-104

Ib/II

A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies

EU-CT-Nummer:  2024-516234-35